Literature DB >> 15081939

Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.

Thirumurthy Velpandian1, Rajani Mathur, Nitin K Agarwal, Brijesh Arora, Lalit Kumar, Suresh K Gupta.   

Abstract

The aim of this study was to develop a rapid and sensitive HPLC method with UV detection for the estimation of imatinib from the plasma of patients with chronic myeloid leukemia (CML). The robustness of the method was checked by conducting first dose pharmacokinetics on blood samples from four patients who had been administered Gleevec (100 mg) in an oral dose. Samples were prepared in a simple and single step by precipitating the plasma proteins with methanol and injecting 50 microl aliquot from supernatant was subjected for analysis. Assay was conducted using a C8 column (250 mm x 4.6 mm, 5 microm particle size) under isocratic elution with 0.02 M potassium dihydrogen phosphate-acetonitrile (7:3, v/v) at a flow rate of 1 ml/min and detected using photodiode array at 265 nm. Calibration plots in spiked plasma were linear in a concentration range of 0.05-25 microg/ml. The inter and intra-day variation of standard curve was <4% (R.S.D.). This method could be a simple and quick method for the estimation of imatinib from the patient's plasma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081939     DOI: 10.1016/j.jchromb.2004.01.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers.

Authors:  Biki Gupta; Bijay Kumar Poudel; Tuan Hiep Tran; Roshan Pradhan; Hyuk-Jun Cho; Jee-Heon Jeong; Beom Soo Shin; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

2.  Conformational landscape and low lying excited states of imatinib.

Authors:  Emil Vinţeler; Nicoleta-Florina Stan; Raluca Luchian; Călin Căinap; João P Prates Ramalho; Vasile Chiş
Journal:  J Mol Model       Date:  2015-03-13       Impact factor: 1.810

3.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

4.  Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.

Authors:  N Singh; L Kumar; R Meena; T Velpandian
Journal:  Eur J Clin Pharmacol       Date:  2009-02-12       Impact factor: 2.953

5.  SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.

Authors:  Onkar Singh; Jason Yongsheng Chan; Keegan Lin; Charles Chuah Thuan Heng; Balram Chowbay
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

6.  Quantitative determination of imatinib stability under various stress conditions.

Authors:  Khalid Mohammed Alkharfy; Rao Muzaffer Ali Khan; Majed Al-Asmari; Baderelddin Hashim Alhadeyah; Ajaz Ahmad
Journal:  J Pharm Bioallied Sci       Date:  2013-01

7.  Monitoring imatinib plasma concentrations in chronic myeloid leukemia.

Authors:  Darlize Hübner Martins; Sandrine Comparsi Wagner; Tamyris Vianna Dos Santos; Lilian de Lima Feltraco Lizot; Marina Venzon Antunes; Marcelo Capra; Rafael Linden
Journal:  Rev Bras Hematol Hemoter       Date:  2011

8.  Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Authors:  Bharathi M Rajamani; Esther Sathya Bama Benjamin; Aby Abraham; Sukanya Ganesan; Kavitha M Lakshmi; Senthamizhselvi Anandan; Sreeja Karathedath; Savitha Varatharajan; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Shaji Ramachandran Velayudhan; Uday P Kulkarni; Anup J Devasia; N A Fouzia; Anu Korula; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.